Background Whether inhaled corticosteroids (ICSs) reduce major adverse cardiovascular events (MACEs) in people with chronic obstructive pulmonary disease (COPD) is debated. Objectives To establish, ...

“We are proud to continue advancing our asthma and COPD inhaled drug program, achieving key clinical development milestones on schedule,” said Xian-Ming Zeng, Ph.D., CEO of Transpire Bio.

It's important to remember that there is no cure for COPD. And while its progression can be slowed, lifestyle changes, prescription medications, lung therapy, and surgery are the proven treatments for ...

“The most important thing everyone with COPD can do is to stop smoking, but there are also inhalers which can help prevent flare ups and also help to open up their airways.” “Pulmonary ...

Part D plans cover FDA-approved medications, including hormonal treatments like estradiol, as long as the cream is considered medically necessary and included in the plan’s formulary.

“Also, carry a reliever inhaler with you at all times because if you do get caught out by something aggregating your asthma, then you have got treatment to take quickly to get on top of your symptoms.

Jan. 7, 2025 /PRNewswire/ -- Qnovia, Inc., a pharmaceutical company developing inhaled therapeutics ... of Asthma, COPD, Vaccine Delivery, Pain Management, and several generic as well as select ...

a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched ...

When patients cannot adhere to inhaler instructions — whether because of cognitive or physical limitations — a nebulized LAMA might offer another method to safely deliver medication. To that end, GOLD ...

a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched pairs of ...

More information: William B Feldman et al, Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study, BMJ (2024).